New designer phenethylamines 2C-C and 2C-P have abuse potential and induce neurotoxicity in rodents

Abou Baker DH, Ibrahim BMM, Hassan NS, Yousuf AF, Gengaihi SE (2020) Exploiting Citrus aurantium seeds and their secondary metabolites in the management of Alzheimer disease. Toxicol Rep 7:723–729. https://doi.org/10.1016/j.toxrep.2020.06.001 Aloizou AM, Siokas V, Sapouni EM et al (2020) Parkinson’s disease and pesticides: are microRNAs the missing link? Sci Total Environ 744:140591. https://doi.org/10.1016/j.scitotenv.2020.140591 Ares-Santos S, Granado N, Oliva I, O’Shea E, Martin ED, Colado MI, Moratalla R (2012) Dopamine D1 receptor deletion strongly reduces neurotoxic effects of methamphetamine. Neurobiol Dis 45(2):810–820. https://doi.org/10.1016/j.nbd.2011.11.005 Asanuma M, Miyazaki I, Funada M (2020) The neurotoxicity of psychoactive phenethylamines “2C series” in cultured monoaminergic neuronal cell lines. Forensic Toxicol 38(2):394–408. https://doi.org/10.1007/s11419-020-00527-w Bachiller S, Jimenez-Ferrer I, Paulus A, Yang Y, Swanberg M, Deierborg T, Boza-Serrano A (2018) Microglia in neurological diseases: a road map to brain-disease dependent-inflammatory response. Front Cell Neurosci 12:488. https://doi.org/10.3389/fncel.2018.00488 Bartlett SE, Enquist J, Hopf FW et al (2005) Dopamine responsiveness is regulated by targeted sorting of D2 receptors. ProcNatlAcadSci USA 102(32):11521–11526. https://doi.org/10.1073/pnas.0502418102 Beirami E, Oryan S, SeyedhosseiniTamijani SM, Ahmadiani A, Dargahi L (2018) Intranasal insulin treatment restores cognitive deficits and insulin signaling impairment induced by repeated methamphetamine exposure. J Cell Biochem 119(2):2345–2355. https://doi.org/10.1002/jcb.26398 Block ML, Zecca L, Hong JS (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8(1):57–69. https://doi.org/10.1038/nrn2038 Botanas CJ, Yoon SS, de la Pena JB et al (2017) The abuse potential of alpha-Piperidinopropiophenone (PIPP) and alpha-Piperidinopentiothiophenone (PIVT), two new synthetic cathinones with piperidine ring substituent. BiomolTher (Seoul) 25(2):122–129. https://doi.org/10.4062/biomolther.2016.241 Braren SH, Drapala D, Tulloch IK, Serrano PA (2014) Methamphetamine-induced short-term increase and long-term decrease in spatial working memory affects protein Kinase M zeta (PKMzeta), dopamine, and glutamate receptors. Front BehavNeurosci 8:438. https://doi.org/10.3389/fnbeh.2014.00438 Cervinski MA, Foster JD, Vaughan RA (2005) Psychoactive substrates stimulate dopamine transporter phosphorylation and down-regulation by cocaine-sensitive and protein kinase C-dependent mechanisms. J BiolChem 280(49):40442–40449. https://doi.org/10.1074/jbc.M501969200 Chauhan H, Killinger BA, Miller CV, Moszczynska A (2014) Single and binge methamphetamine administrations have different effects on the levels of dopamine D2 autoreceptor and dopamine transporter in rat striatum. Int J MolSci 15(4):5884–5906. https://doi.org/10.3390/ijms15045884 Cole RD, Wolsh C, Zimmerman M, Harrington E, Gould TJ, Parikh V (2019) Adolescent and adult nicotine exposure differentially impacts oral nicotine and oral saccharin self-administration in mice. Behav Brain Res 359:836–844. https://doi.org/10.1016/j.bbr.2018.07.019 Cole RL, Konradi C, Douglass J, Hyman SE (1995) Neuronal adaptation to amphetamine and dopamine: molecular mechanisms of prodynorphin gene regulation in rat striatum. Neuron 14(4):813–823. https://doi.org/10.1016/0896-6273(95)90225-2 Çomaklı S, Sevim Ç, Kontadakis G et al (2019) Acute glufosinate-based herbicide treatment in rats leads to increased ocular interleukin-1β and c-Fos protein levels, as well as intraocular pressure. Toxicol Rep 6:155–160. https://doi.org/10.1016/j.toxrep.2019.01.004 Cornish JL, Hunt GE, Robins L, McGregor IS (2012) Regional c-Fos and FosB/DeltaFosB expression associated with chronic methamphetamine self-administration and methamphetamine-seeking behavior in rats. Neuroscience 206:100–114. https://doi.org/10.1016/j.neuroscience.2012.01.004 Curtin K, Fleckenstein AE, Robison RJ, Crookston MJ, Smith KR, Hanson GR (2015) Methamphetamine/amphetamine abuse and risk of Parkinson’s disease in Utah: a population-based assessment. Drug Alcohol Depend 146:30–38. https://doi.org/10.1016/j.drugalcdep.2014.10.027 Custodio RJP, Sayson LV, Botanas CJ et al (2019) 25B-NBOMe, a novel N-2-methoxybenzyl-phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: Evidence of abuse potential. Addict Biol. https://doi.org/10.1111/adb.12850 Dardiotis E, Aloizou AM, Sakalakis E et al (2020) Organochlorine pesticide levels in Greek patients with Parkinson’s disease. Toxicol Rep 7:596–601. https://doi.org/10.1016/j.toxrep.2020.03.011 Daza-Losada M, Ribeiro Do Couto B, Manzanedo C, Aguilar MA, Rodriguiz-Arias M, Minarro J (2007) Rewarding effects and reinstatement of MDMA-induced CPP in adolescent mice. Neuropsychopharmacology 32(8):1750–1759. https://doi.org/10.1038/sj.npp.1301309 Davidson C, Gow AJ, Lee TH, Ellinwood EH (2001) Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 36(1):1–22. https://doi.org/10.1016/s0165-0173(01)00054-6 Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM (2013) 2C or not 2C: phenethylamine designer drug review. J Med Toxicol 9(2):172–178. https://doi.org/10.1007/s13181-013-0295-x Elmore JS, Decker AM, Sulima A, Rice KC, Partilla JS, Blough BE, Baumann MH (2018) Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats. Neuropharmacology 142:240–250. https://doi.org/10.1016/j.neuropharm.2018.02.033 Eshleman AJ, Forster MJ, Wolfrum KM, Johnson RA, Janowsky A, Gatch MB (2014) Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function. Psychopharmacology 231(5):875–888. https://doi.org/10.1007/s00213-013-3303-6 FDA (2017) Assessment of abuse potential of drugs guidance for industry. Food and Drug administration, pp 1–37. Retrieved from https://www.fda.gov/media/116739/download Foster JD, Vaughan RA (2017) Phosphorylation mechanisms in dopamine transporter regulation. J ChemNeuroanat 83–84:10–18. https://doi.org/10.1016/j.jchemneu.2016.10.004 Galaj E, Bi GH, Moore A et al (2020) Beta-caryophyllene inhibits cocaine addiction-related behavior by activation of PPARα and PPARγ: repurposing a FDA-approved food additive for cocaine use disorder. Neuropsychopharmacology. https://doi.org/10.1038/s41386-020-00885-4 Gannon BM, Baumann MH, Walther D et al (2018) The abuse-related effects of pyrrolidine-containing cathinones are related to their potency and selectivity to inhibit the dopamine transporter. Neuropsychopharmacology. https://doi.org/10.1038/s41386-018-0209-3 Gehrke BJ, Harrod SB, Cass WA, Bardo MT (2003) The effect of neurotoxic doses of methamphetamine on methamphetamine-conditioned place preference in rats. Psychopharmacology 166(3):249–257. https://doi.org/10.1007/s00213-002-1318-5 Gilbert DB, Cooper SJ (1985) β-Phenylethylamine and amphetamine compared in tests of anorexia and place-preference conditioning. In: Boulton AA, Maitre L, Bieck PR, Riederer P (eds) Neuropsychopharmacology of the trace amines: experimental and clinical aspects. Humana Press, Totowa, NJ, pp 187–193 GovTrack.us (2012) S. 3187 112th Congress: food and drug administration safety and innovation act., 112th edn. Retrieved from https://www.govinfo.gov/content/pkg/BILLS-112s3187enr/pdf/BILLS-112s3187enr.pdf Hansen DV, Hanson JE, Sheng M (2018) Microglia in Alzheimer’s disease. J Cell Biol 217(2):459–472. https://doi.org/10.1083/jcb.201709069 Ikemoto S, Wise RA (2002) Rewarding effects of the cholinergic agents carbachol and neostigmine in the posterior ventral tegmental area. J Neurosci 22(22):9895. https://doi.org/10.1523/JNEUROSCI.22-22-09895.2002 Liddelow SA, Guttenplan KA, Clarke LE et al (2017) Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541:481–487. https://doi.org/10.1038/nature21029 Luikinga SJ, Perry CJ, Madsen HB, Lawrence AJ, Kim JH (2019) Effects of methamphetamine exposure on fear learning and memory in adult and adolescent rats. Neurochem Res 44(9):2081–2091. https://doi.org/10.1007/s11064-019-02845-x Nagai F, Nonaka R, Satoh HisashiKamimura K (2007) The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 559(2–3):132–137. https://doi.org/10.1016/j.ejphar.2006.11.075 Nestler EJ (2012) Transcriptional mechanisms of drug addiction. ClinPsychopharmacolNeurosci 10(3):136–143. https://doi.org/10.9758/cpn.2012.10.3.136 Noda Y, Mouri A, Ando Y et al (2010) Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems. Int J Neuropsychopharm 13(10):1343–1354. https://doi.org/10.1017/S1461145710000222 Rickli A, Luethi D, Reinisch J, Buchy D, Hoener MC, Liechti ME (2015) Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology 99:546–553. https://doi.org/10.1016/j.neuropharm.2015.08.034 Russo SJ, Nestler EJ (2013) The brain reward circuitry in mood disorders. Nat Rev Neurosci 14(9):609–625. https://doi.org/10.1038/nrn3381 Seo JY, Hur KH, Ko YH et al (2019) A novel designer drug, 25N-NBOMe, exhibits abuse potential via the dopaminergic system in rodents. Brain Res Bull 152:19–26. https://doi.org/10.1016/j.brainresbull.2019.07.002 Shulgin AT, Shulgin A (1990) PiHKAL, The chmical love story. Transform Press, Berkely Siokas V, Aslanidou P, Aloizou AM et al (2020) Does the CD33 rs3865444 polymorphism confer susceptibility to alzheimer’s disease? J MolNeurosci 70(6):851–860. https://doi.org/10.1007/s12031-020-01507-w Sofroniew MV, Vinters HV (2010) Astrocytes: biology and pathology. ActaNeuropathol 119(1):7–35. https://doi.org/10.1007/s00401-009-0619-8 Spanagel R (2017) Animal models of addiction. Dialog ClinNeurosci 19(3):247–258. https://doi.org/10.31887/DCNS.2017.19.3/rspanagel Stephenson CP, Hunt GE, Topple AN, McGregor IS (1999) The distribution of 3,4-methylenedioxymethamphetamine “Ecstasy”-induced c-fos expression in rat brain. Neuroscience 92(3):1011–1023. https://doi.org/10.1016/S0306-4522(99)00049-4 Stoller A, Dolder PC, Bodmer M et al (2017) Mistaking 2C-P for 2C-B: what a difference a letter makes. J Anal Toxicol 41(1):77–79. https://doi.org/10.1093/jat/bkw108 Teixeira-Gomes A, Costa VM, Feio-Azevedo R, BastosMde L, Carvalho F, Capela JP (2015) The neurotoxicity of amphetamines during the adolescent period. Int J Dev Neurosci 41:44–62. https://doi.org/10.1016/j.ijdevneu.2014.12.001 Thomas DM, Walker PD, Benjamins JA, Geddes TJ, Kuhn DM (2004) Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J PharmacolExpTher 311(1):1–7. https://doi.org/10.1124/jpet.104.070961 Volkow ND, Fowler JS, Wang GJ (2002) Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. BehavPharmacol 13(5–6):355–366. https://doi.org/10.1097/00008877-200209000-00008 Volkow ND, Wise RA, Baler R (2017) The dopamine motive system: implications for drug and food addiction. Nat Rev Neurosci 18(12):741–752. https://doi.org/10.1038/nrn.2017.130 Xu W, Zhu JP, Angulo JA (2005) Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors. Synapse (New York, NY) 58(2):110–121. https://doi.org/10.1002/syn.20185